Potential photoactivated metallopharmaceuticals: from active molecules to supported drugs.
Apart from cisplatin and some derivatives successful metallopharmaceuticals are still scarce in antitumour therapy. Although novel metal complexes have been investigated in preclinical settings several promising compounds failed in different phases. With the rise of new anticancer compounds new activation strategies have also evolved. Photochemical activation is one of the most important concepts as it uses pro-drugs whose activity can be triggered by light. This strategy offers the possibility to control the location, timing, and dosage of the therapeutic metal complex. Recent developments in the photoactivation of potential metallopharmaceuticals are summarized. Immobilisation of those drugs on solid matrices, such as films, particles, gels, and fibers, is an emerging field and recent findings are also discussed.
Crespy
Daniel
D
Max Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.
Landfester
Katharina
K
Schubert
Ulrich S
US
Schiller
Alexander
A
D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D056831:Coordination Complexes / Q000737:chemistry / Q000627:therapeutic use; D004247:DNA / Q000737:chemistry; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry; D009369:Neoplasms / Q000188:drug therapy; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D017319:Photosensitizing Agents / Q000737:chemistry / Q000627:therapeutic use; D011355:Prodrugs / Q000737:chemistry / Q000627:therapeutic use
D000970:Antineoplastic Agents; D056831:Coordination Complexes; D004364:Pharmaceutical Preparations; D017319:Photosensitizing Agents; D011355:Prodrugs; D004247:DNA